AMP-activated protein kinase at the nexus of therapeutic skeletal muscle plasticity in Duchenne muscular dystrophy

Trends in Molecular Medicine

Volumn 19, Issue 10, 2013, Pages 614-624

  Ljubicic, Vladimir ^a   Jasmin, Bernard J ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

AICAR; AMPK; Autophagy; DMD; Fiber type; Utrophin A

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; 6,7 DIHYDRO 4 HYDROXY 3 (2' HYDROXY 1,1' BIPHENYL 4 YL) 6 OXOTHIENO[2,3 B]PYRIDINE 5 CARBONITRILE; [2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; DYSTROPHIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE;

AUTOPHAGY; DRUG TARGETING; DUCHENNE MUSCULAR DYSTROPHY; HUMAN; INTRACELLULAR SIGNALING; MUSCLE ATROPHY; MUSCLE CELL; NONHUMAN; OXIDATION; PHENOTYPIC PLASTICITY; REVIEW; SKELETAL MUSCLE;

MUS;

AICAR; AMPK; AUTOPHAGY; DMD; FIBER TYPE; UTROPHIN A;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; AUTOPHAGY; HUMANS; MUSCLE FIBERS, SKELETAL; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, DUCHENNE; OXIDATION-REDUCTION;

EID: 84884813468     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2013.07.002     Document Type: Review

References (109)

1. Bushby K., et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 2010, 9:77-93.
2. Bushby K., et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol. 2010, 9:177-189.
3. Hoffman E.P., et al. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 1987, 51:919-928.
4. Kalman L., et al. Quality assurance for Duchenne and Becker muscular dystrophy genetic testing: development of a genomic DNA reference material panel. J. Mol. Diagn. 2011, 13:167-174.
5. Bennett R.R., et al. Detection of mutations in the dystrophin gene via automated DHPLC screening and direct sequencing. BMC Genet. 2001, 2:17.
6. Davies K.E., Nowak K.J. Molecular mechanisms of muscular dystrophies: old and new players. Nat. Rev. Mol. Cell Biol. 2006, 7:762-773.
7. Blake D.J., et al. Function and genetics of dystrophin and dystrophin-related proteins in muscle. Physiol. Rev. 2002, 82:291-329.
8. Pilgram G.S., et al. The roles of the dystrophin-associated glycoprotein complex at the synapse. Mol. Neurobiol. 2010, 41:1-21.
9. Ervasti J.M., Campbell K.P. Dystrophin and the membrane skeleton. Curr. Opin. Cell Biol. 1993, 5:82-87.
10. Mendell J.R., et al. Gene therapy for muscular dystrophy: lessons learned and path forward. Neurosci. Lett. 2012, 527:90-99.
11. Pichavant C., et al. Current status of pharmaceutical and genetic therapeutic approaches to treat DMD. Mol. Ther. 2011, 19:830-840.
12. Webster C., et al. Fast muscle fibers are preferentially affected in Duchenne muscular dystrophy. Cell 1988, 52:503-513.
13. Moens P., et al. Increased susceptibility of EDL muscles from mdx mice to damage induced by contractions with stretch. J. Muscle Res. Cell Motil. 1993, 14:446-451.
14. Gramolini A.O., et al. Increased expression of utrophin in a slow vs. a fast muscle involves posttranscriptional events. Am. J. Physiol. Cell Physiol. 2001, 281:C1300-C1309.
15. Chakkalakal J.V., et al. Expression of utrophin A mRNA correlates with the oxidative capacity of skeletal muscle fiber types and is regulated by calcineurin/NFAT signaling. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:7791-7796.
16. Chakkalakal J.V., et al. Stimulation of calcineurin signaling attenuates the dystrophic pathology in mdx mice. Hum. Mol. Genet. 2004, 13:379-388.
17. Angus L.M., et al. Calcineurin-NFAT signaling, together with GABP and peroxisome PGC-1α, drives utrophin gene expression at the neuromuscular junction. Am. J. Physiol. Cell Physiol. 2005, 289:C908-C917.
18. 2+/calmodulin signaling exacerbates the dystrophic phenotype in mdx mouse muscle. Hum. Mol. Genet. 2006, 15:1423-1435.
19. Miura P., et al. Pharmacological activation of PPARβ/δ stimulates utrophin A expression in skeletal muscle fibers and restores sarcolemmal integrity in mature mdx mice. Hum. Mol. Genet. 2009, 18:4640-4649.
20. Ljubicic V., et al. Chronic AMPK activation evokes the slow, oxidative myogenic program and triggers beneficial adaptations in mdx mouse skeletal muscle. Hum. Mol. Genet. 2011, 20:3478-3493.
21. Ljubicic V., et al. Chronic AMPK stimulation attenuates adaptive signaling in dystrophic skeletal muscle. Am. J. Physiol. Cell Physiol. 2012, 302:C110-C121.
22. Stupka N., et al. The calcineurin signal transduction pathway is essential for successful muscle regeneration in mdx dystrophic mice. Acta Neuropathol. 2004, 107:299-310.
23. Stupka N., et al. Activated calcineurin ameliorates contraction-induced injury to skeletal muscles of mdx dystrophic mice. J. Physiol. 2006, 575:645-656.
24. Handschin C., et al. PGC-1α regulates the neuromuscular junction program and ameliorates Duchenne muscular dystrophy. Genes Dev. 2007, 21:770-783.
25. Hori Y.S., et al. Resveratrol ameliorates muscular pathology in the dystrophic mdx mouse, a model for Duchenne muscular dystrophy. J. Pharmacol. Exp. Ther. 2011, 338:784-794.
26. Selsby J.T., et al. Rescue of dystrophic skeletal muscle by PGC-1α involves a fast to slow fiber type shift in the mdx mouse. PLoS ONE 2012, 7:e30063.
27. Gordon B.S., et al. Resveratrol decreases inflammation and increases utrophin gene expression in the mdx mouse model of Duchenne muscular dystrophy. Clin. Nutr. 2013, 32:104-111.
28. Baltgalvis K.A., et al. Exercise training improves plantarflexor muscle function in mdx mice. Med. Sci. Sports Exerc. 2012, 44:1671-1679.
29. Godin R., et al. Peroxisome proliferator-activated receptor γ coactivator 1-gene α transfer restores mitochondrial biomass and improves mitochondrial calcium handling in post-necrotic mdx mouse skeletal muscle. J. Physiol. 2012, 590:5487-5502.
30. Blanchet E., et al. E2F transcription factor-1 deficiency reduces pathophysiology in the mouse model of Duchenne muscular dystrophy through increased muscle oxidative metabolism. Hum. Mol. Genet. 2012, 21:3910-3917.
31. Jahnke V.E., et al. Metabolic remodeling agents show beneficial effects in the dystrophin-deficient mdx mouse model. Skelet. Muscle 2012, 2:16.
32. Bueno Júnior C.R., et al. Combined effect of AMPK/PPAR agonists and exercise training in mdx mice functional performance. PLoS ONE 2012, 7:e45699.
33. von Maltzahn J., et al. Wnt7a treatment ameliorates muscular dystrophy. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:20614-20619.
34. Love D.R., et al. An autosomal transcript in skeletal muscle with homology to dystrophin. Nature 1989, 339:55-58.
35. Matsumura K., et al. Association of dystrophin-related protein with dystrophin-associated proteins in mdx mouse muscle. Nature 1992, 360:588-591.
36. Deconinck A.E., et al. Utrophin-dystrophin-deficient mice as a model for Duchenne muscular dystrophy. Cell 1997, 90:717-727.
37. Grady R.M., et al. Skeletal and cardiac myopathies in mice lacking utrophin and dystrophin: a model for Duchenne muscular dystrophy. Cell 1997, 90:729-738.
38. Tinsley J., et al. Expression of full-length utrophin prevents muscular dystrophy in mdx mice. Nat. Med. 1998, 4:1441-1444.
39. Rafael J.A., et al. Skeletal muscle-specific expression of a utrophin transgene rescues utrophin-dystrophin deficient mice. Nat. Genet. 1998, 19:79-82.
40. Chin E.R., et al. A calcineurin-dependent transcriptional pathway controls skeletal muscle fiber type. Genes Dev. 1998, 12:2499-2509.
41. Long Y.C., Zierath J.R. Influence of AMP-activated protein kinase and calcineurin on metabolic networks in skeletal muscle. Am. J. Physiol. Endocrinol. Metab. 2008, 295:E545-E552.
42. Parsons S.A., et al. Genetic disruption of calcineurin improves skeletal muscle pathology and cardiac disease in a mouse model of limb-girdle muscular dystrophy. J. Biol. Chem. 2007, 282:10068-10078.
43. Lin J., et al. Transcriptional co-activator PGC-1α drives the formation of slow-twitch muscle fibres. Nature 2002, 418:797-801.
44. Lira V.A., et al. PGC-1α regulation by exercise training and its influences on muscle function and insulin sensitivity. Am. J. Physiol. Endocrinol. Metab. 2010, 299:E145-E161.
45. Gramolini A.O., et al. Induction of utrophin gene expression by heregulin in skeletal muscle cells: role of the N-box motif and GA binding protein. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:3223-3227.
46. Khurana T.S., et al. Activation of utrophin promoter by heregulin via the ets-related transcription factor complex GA-binding protein alpha/beta. Mol. Biol. Cell 1999, 10:2075-2086.
47. Ehrenborg E., Krook A. Regulation of skeletal muscle physiology and metabolism by peroxisome proliferator-activated receptor delta. Pharmacol. Rev. 2009, 61:373-393.
48. Hardie D.G. Sensing of energy and nutrients by AMP-activated protein kinase. Am. J. Clin. Nutr. 2011, 93:891S-896S.
49. Lagouge M., et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1α. Cell 2006, 127:1109-1122.
50. Dolinsky V.W., et al. Improvements in skeletal muscle strength and cardiac function induced by resveratrol during exercise training contribute to enhanced exercise performance in rats. J. Physiol. 2012, 590:2783-2799.
51. Moorwood C., et al. Drug discovery for Duchenne muscular dystrophy via utrophin promoter activation screening. PLoS ONE 2011, 6:e26169.
52. Risérus U., et al. Activation of peroxisome proliferator-activated receptor (PPAR)δ promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men. Diabetes 2008, 57:332-339.
53. Bays H.E., et al. MBX-8025, a novel peroxisome proliferator receptor-δ agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin. J. Clin. Endocrinol. Metab. 2011, 96:2889-2897.
54. Timmers S., et al. The journey of resveratrol from yeast to human. Aging (Albany, N. Y.) 2012, 4:146-158.
55. Witczak C.A., et al. AMP-activated protein kinase in skeletal muscle: from structure and localization to its role as a master regulator of cellular metabolism. Cell. Mol. Life Sci. 2008, 65:3737-3755.
56. McGee S.L., Hargreaves M. AMPK-mediated regulation of transcription in skeletal muscle. Clin. Sci. (Lond.) 2010, 118:507-518.
57. Krämer D.K., et al. Role of AMP kinase and PPARδ in the regulation of lipid and glucose metabolism in human skeletal muscle. J. Biol. Chem. 2007, 282:19313-19320.
58. Narkar V.A., et al. AMPK and PPARδ agonists are exercise mimetics. Cell 2008, 134:405-415.
59. Gan Z., et al. The nuclear receptor PPARβ/δ programs muscle glucose metabolism in cooperation with AMPK and MEF2. Genes Dev. 2011, 25:2619-2630.
60. Fujii N., et al. Role of AMP-activated protein kinase in exercise capacity, whole body glucose homeostasis, and glucose transport in skeletal muscle - insight from analysis of a transgenic mouse model. Diabetes Res. Clin. Pract. 2007, 77:S92-S98.
61. Röckl K.S., et al. Skeletal muscle adaptation to exercise training: AMP-activated protein kinase mediates muscle fiber type shift. Diabetes 2007, 56:2062-2069.
62. Barré L., et al. Genetic model for the chronic activation of skeletal muscle AMP-activated protein kinase leads to glycogen accumulation. Am. J. Physiol. Endocrinol. Metab. 2007, 292:E802-E811.
63. Garcia-Roves P.M., et al. Gain-of-function R225Q mutation in AMP-activated protein kinase γ3 subunit increases mitochondrial biogenesis in glycolytic skeletal muscle. J. Biol. Chem. 2008, 283:35724-35734.
64. Winder W.W., et al. Activation of AMP-activated protein kinase increases mitochondrial enzymes in skeletal muscle. J. Appl. Physiol. 2000, 88:2219-2226.
65. Suwa M., et al. Effects of chronic AICAR treatment on fiber composition, enzyme activity, UCP3, and PGC-1 in rat muscles. J. Appl. Physiol. 2003, 95:960-968.
66. Fillmore N., et al. Chronic AMP-activated protein kinase activation and a high-fat diet have an additive effect on mitochondria in rat skeletal muscle. J. Appl. Physiol. 2010, 109:511-520.
67. Ren J.M., et al. Effects of β-guanidinopropionic acid-feeding on the patterns of myosin isoforms in rat fast-twitch muscle. Pflugers Arch. 1995, 430:389-393.
68. Bergeron R., et al. Chronic activation of AMP kinase results in NRF-1 activation and mitochondrial biogenesis. Am. J. Physiol. Endocrinol. Metab. 2001, 281:E1340-E1346.
69. Zong H., et al. AMP kinase is required for mitochondrial biogenesis in skeletal muscle in response to chronic energy deprivation. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:15983-15987.
70. Williams D.B., et al. Muscle-specific differences in the response of mitochondrial proteins to β-GPA feeding: an evaluation of potential mechanisms. Am. J. Physiol. Endocrinol. Metab. 2009, 296:E1400-E1408.
71. Kotelnikova E., et al. Novel approach to meta-analysis of microarray datasets reveals muscle remodeling-related drug targets and biomarkers in Duchenne muscular dystrophy. PLoS Comput. Biol. 2012, 8:e1002365.
72. Pauly M., et al. AMPK activation stimulates autophagy and ameliorates muscular dystrophy in the mdx mouse diaphragm. Am. J. Pathol. 2012, 181:583-592.
73. Sandri M. Autophagy in skeletal muscle. FEBS Lett. 2010, 584:1411-1416.
74. Levine B., Kroemer G. Autophagy in the pathogenesis of disease. Cell 2008, 132:27-42.
75. Malicdan M.C., Nishino I. Autophagy in lysosomal myopathies. Brain Pathol. 2012, 22:82-88.
76. Lieberman A.P., et al. Autophagy in lysosomal storage disorders. Autophagy 2012, 8:719-730.
77. Ramos F.J., et al. Rapamycin reverses elevated mTORC1 signaling in lamin A/C-deficient mice, rescues cardiac and skeletal muscle function, and extends survival. Sci. Transl. Med. 2012, 4:144ra103.
78. Mitsuhashi S., et al. Muscle choline kinase β defect causes mitochondrial dysfunction and increased mitophagy. Hum. Mol. Genet. 2011, 20:3841-3851.
79. Carmignac V., et al. Autophagy is increased in laminin α2 chain-deficient muscle and its inhibition improves muscle morphology in a mouse model of MDC1A. Hum. Mol. Genet. 2011, 20:4891-4902.
80. Irwin W.A., et al. Mitochondrial dysfunction and apoptosis in myopathic mice with collagen VI deficiency. Nat. Genet. 2003, 35:367-371.
81. Grumati P., et al. Autophagy is defective in collagen VI muscular dystrophies, and its reactivation rescues myofiber degeneration. Nat. Med. 2010, 16:1313-1320.
82. De Palma C., et al. Autophagy as a new therapeutic target in Duchenne muscular dystrophy. Cell Death Dis. 2012, 3:e418.
83. Lee J.W., et al. The association of AMPK with ULK1 regulates autophagy. PLoS ONE 2010, 5:e15394.
84. Kim J., et al. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat. Cell Biol. 2011, 13:132-141.
85. Egan D.F., et al. Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase connects energy sensing to mitophagy. Science 2011, 331:456-461.
86. Ravikumar B., et al. Regulation of mammalian autophagy in physiology and pathophysiology. Physiol. Rev. 2010, 90:1383-1435.
87. Sanchez A.M., et al. AMPK promotes skeletal muscle autophagy through activation of forkhead FoxO3a and interaction with Ulk1. J. Cell. Biochem. 2012, 113:695-710.
88. Romanello V., et al. Mitochondrial fission and remodelling contributes to muscle atrophy. EMBO J. 2010, 29:1774-1785.
89. Jamart C., et al. Modulation of autophagy and ubiquitin-proteasome pathways during ultra-endurance running. J. Appl. Physiol. 2012, 112:1529-1537.
90. Paul P.K., et al. Targeted ablation of TRAF6 inhibits skeletal muscle wasting in mice. J. Cell Biol. 2010, 191:1395-1411.
91. He C., et al. Exercise-induced BCL2-regulated autophagy is required for muscle glucose homeostasis. Nature 2012, 481:511-515.
92. Viollet B., et al. AMPK inhibition in health and disease. Crit. Rev. Biochem. Mol. Biol. 2010, 45:276-295.
93. Cuthbertson D.J., et al. 5-Aminoimidazole-4-carboxamide 1-β-d-ribofuranoside acutely stimulates skeletal muscle 2-deoxyglucose uptake in healthy men. Diabetes 2007, 56:2078-2084.
94. Drew B.G., Kingwell B.A. Acadesine, an adenosine-regulating agent with the potential for widespread indications. Expert Opin. Pharmacother. 2008, 9:2137-2144.
95. Boon H., et al. Intravenous AICAR administration reduces hepatic glucose output and inhibits whole body lipolysis in type 2 diabetic patients. Diabetologia 2008, 51:1893-1900.
96. Viollet B., et al. Cellular and molecular mechanisms of metformin: an overview. Clin. Sci. (Lond.) 2012, 122:253-270.
97. Suwa M., et al. Metformin increases the PGC-1α protein and oxidative enzyme activities possibly via AMPK phosphorylation in skeletal muscle in vivo. J. Appl. Physiol. 2006, 101:1685-1692.
98. Bellinger A.M., et al. Hypernitrosylated ryanodine receptor calcium release channels are leaky in dystrophic muscle. Nat. Med. 2009, 15:325-330.
99. Andersson D.C., et al. Leaky ryanodine receptors in β-sarcoglycan deficient mice: a potential common defect in muscular dystrophy. Skelet. Muscle 2012, 2:9.
100. Lanner J.T., et al. AICAR prevents heat-induced sudden death in RyR1 mutant mice independent of AMPK activation. Nat. Med. 2012, 18:244-251.
101. Hawley S.A., et al. The ancient drug salicylate directly activates AMP-activated protein kinase. Science 2012, 336:918-922.
102. Blake D.J., et al. Characterization of a 4.8kb transcript from the Duchenne muscular dystrophy locus expressed in Schwannoma cells. Hum. Mol. Genet. 1992, 1:103-109.
103. Mizushima N., et al. Autophagy fights disease through cellular self-digestion. Nature 2008, 451:1069-1075.
104. Das G., et al. Regulation and function of autophagy during cell survival and cell death. Cold Spring Harb. Perspect. Biol. 2012, 4:a008813.
105. Youle R.J., Narendra D.P. Mechanisms of mitophagy. Nat. Rev. Mol. Cell Biol. 2011, 12:9-14.
106. Park C.E., et al. Resveratrol stimulates glucose transport in C2C12 myotubes by activating AMP-activated protein kinase. Exp. Mol. Med. 2007, 39:222-229.
107. Um J.H., et al. AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol. Diabetes 2010, 59:554-563.
108. Cantó C., et al. Interdependence of AMPK and SIRT1 for metabolic adaptation to fasting and exercise in skeletal muscle. Cell Metab. 2010, 11:213-219.
109. Markert C.D., et al. Exercise and Duchenne muscular dystrophy: toward evidence-based exercise prescription. Muscle Nerve 2011, 43:464-478.